Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 15/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227444 | 0.87 | CCR2 (0.47) | CCR2HSP90AA1HSP90AB1RAB9A | |
| SCHEMBL5030287 | 0.85 | CCR2 (0.36) | CCR2HSP90AA1HSP90AB1RAB9ACYP2D6 | |
| SCHEMBL5233939 | 0.85 | CCR2 (0.40) | CCR2RAB9ACYP2D6KCNH2 | |
| SCHEMBL5033609 | 0.84 | CCR2 (0.53) | CCR2CYP2D6KCNH2 | |
| SCHEMBL5030311 | 0.76 | CCR2 (0.41) | CCR2RAB9ACYP2D6KCNH2 | |
| SCHEMBL5030282 | 0.76 | CCR2 (0.41) | CCR2RAB9ACYP2D6KCNH2 | |
| SCHEMBL5033552 | 0.75 | CCR2 (0.51) | CCR2CYP2D6KCNH2 | |
| SCHEMBL5033540 | 0.75 | CCR2 (0.51) | CCR2CYP2D6KCNH2 | |
| SCHEMBL5033606 | 0.73 | CCR2 (0.49) | CCR2RAB9ACYP2D6KCNH2 | |
| SCHEMBL5033602 | 0.73 | CCR2 (0.49) | CCR2RAB9ACYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | CCR2 3/4885HSP90AA1 2608/4885HSP90AB1 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.